Detection of exon skipping events in BRCA1 RNA using MLPA kit P002

Molecular Biology Reports

Volumn 39, Issue 7, 2012, Pages 7429-7433

  Brandão, Rita D ^a   Tserpelis, Demis ^b   García, Encarna Gómez ^a,b   Blok, Marinus J ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

BRCA1; Breast cancer; Multiplex ligation probe amplification (MLPA); RNA; RNA splicing

Indexed keywords

BRCA1 PROTEIN; COMPLEMENTARY DNA; DEOXYRIBONUCLEASE I; PUROMYCIN; RNA;

ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DIAGNOSTIC VALUE; EXON SKIPPING; FAMILIAL CANCER; FEMALE; GENERAL DEVICE; HEREDITARY BREAST OVARIAN SYNDROME; HUMAN; HUMAN CELL; LYMPHOCYTE CULTURE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PILOT STUDY; RELIABILITY; REPRODUCIBILITY; RNA ANALYSIS;

BRCA1 PROTEIN; BREAST NEOPLASMS; CELLS, CULTURED; DNA; DNA PRIMERS; EXONS; FEMALE; GENES, BRCA1; HUMANS; MULTIPLEX POLYMERASE CHAIN REACTION; OVARIAN NEOPLASMS; REPRODUCIBILITY OF RESULTS; RNA; SEQUENCE DELETION;

EID: 84864290149     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-012-1575-2     Document Type: Article

References (17)

1. Cartegni L, Chew SL, Krainer AR (2002) Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 3(4):285-298 (Pubitemid 34279797)
2. Harland M, Mistry S, Bishop DT, Newton Bishop JA (2001) A deep intronic mutation in CDKN2A is associated with disease in a subset of melanoma pedigrees. Hum Mol Genet 10(23):2679-2686. doi:10.1093/hmg/10.23.2679 (Pubitemid 33133409)
3. Homolova K, Zavadakova P, Doktor TK, Schroeder LD, Kozich V, Andresen BS (2010) The deep intronic c.903?469TC mutation in the MTRR gene creates an SF2/ASF binding exonic splicing enhancer, which leads to pseudoexon activation and causes the cblE type of homocystinuria. Hum Mutat 31(4):437-444. doi:10.1002/humu.21206
4. Bonatti F, Pepe C, Tancredi M, Lombardi G, Aretini P, Sensi E, Falaschi E, Cipollini G, Bevilacqua G, Caligo MA (2006) RNA-based analysis of BRCA1 and BRCA2 gene alterations. Cancer Genet Cytogenet 170(2):93-101 (Pubitemid 44442459)
5. Bonnet C, Krieger S, Vezain M, Rousselin A, Tournier I, Martins A, Berthet P, Chevrier A, Dugast C, Layet V, Rossi A, Lidereau R, Frebourg T, Hardouin A, Tosi M (2008) Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene. J Med Genet 45(7):438-446. doi:10.1136/jmg.2007.056895 (Pubitemid 351977134)
6. Whiley PJ, Guidugli L, Walker LC, Healey S, Thompson BA, Lakhani SR, Da Silva LM, Investigators K, Tavtigian SV, Goldgar DE, Brown MA, Couch FJ, Spurdle AB (2011) Splicing and multifactorial analysis of intronic BRCA1 and BRCA2 sequence variants identifies clinically significant splicing aberrations up to 12 nucleotides from the intron/exon boundary. Hum Mutat 32(6):678-687. doi:10.1002/humu.21495
7. Brandão RD, van Roozendaal K, Tserpelis D, García EG, Blok MJ (2011) Characterisation of unclassified variants in the BRCA1/2 genes with a putative effect on splicing. Breast Cancer Res Treat 129(3):971-982. doi:10.1007/s10549-011-1599-7
8. Sammeth M, Foissac S, Guigó R (2008) A general definition and nomenclature for alternative splicing events. PLoS Comput Biol 4 (8). doi:10.1371/journal.pcbi.1000147
9. Kesari A, Pirra LN, Bremadesam L, McIntyre O, Gordon E, Dubrovsky AL, Viswanathan V, Hoffman EP (2008) Integrated DNA, c DNA, and protein studies in Becker muscular dystrophy show high exception to the reading frame rule. Hum Mutat 29(5):728-737. doi:10.1002/humu.20722 (Pubitemid 351614598)
10. Hogervorst FBL, Nederlof PM, Gille JJP, McElgunn CJ, Gripp-eling M, Pruntel R, Regnerus R, van Welsem T, van Spaendonk R, Menko FH, Kluijt I, Dommering C, Verhoef S, Schouten JP, van't Veer LJ, Pals G (2003) Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res 63(7):1449-1453 (Pubitemid 36373627)
11. Petrij-Bosch A, Peelen T, van Vliet M, van Eijk R, Olmer R, Drüsedau M, Hogervorst F, Hageman S, Arts P, Ligtenberg M, Meijers-Heijboer H, Klijn J, Vasen H, Cornelisse C, van 't Veer L, Bakker E, van Ommen G, Devilee P (1997) BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet 17(4):341-345 (Pubitemid 27476002)
12. Carter MS, Doskow J, Morris P, Li S, Nhim RP, Sandstedt S, Wilkinson MF (1995) A regulatory mechanism that detects premature nonsense codons in T-cell receptor transcripts in vivo is reversed by protein synthesis inhibitors in vitro. J Biol Chem 270(48):28995-29003. doi:10.1074/jbc.270.48.28995
13. Barbaro M, Kotajärvi M, Harper P, Floderus Y (2011) Identification of an AluY-mediated deletion of exon 5 in the CPOX gene by MLPA analysis in patients with hereditary coproporphyria. Clin Genet:no-no. doi: 10.1111/j.1399-0004.2011.01628.x
14. Harteveld CL, Voskamp A, Phylipsen M, Akkermans N, den Dunnen JT, White SJ, Giordano PC (2005) Nine unknown rearrangements in 16p13.3 and 11p15.4 causing a and b-thalassaemia characterised by high resolution multiplex ligation-dependent probe amplification. J Med Genet 42(12):922-931. doi: 10.1136/jmg.2005.033597 (Pubitemid 41811314)
15. Nyström A-M, Ekvall S, Thuresson A-C, Denayer E, Legius E, Kamali-Moghaddam M, Westermark B, Annerén G, Bondeson M-L (2010) Investigation of gene dosage imbalances in patients with Noonan syndrome using multiplex ligation-dependent probe amplification analysis. Euro J Med Genet 53(3):117-121
16. Kellander M, Riley M, Liu C Application Note: GeneMarker® Software for Multiplex Ligation-dependent Probe Amplification TM (MLPA). SoftGenetics LLC
17. Levin J, Berger M, Adiconis X, Rogov P, Melnikov A, Fennell T, Nusbaum C, Garraway L, Gnirke A (2009) Targeted next-gen eration sequencing of a cancer transcriptome enhances detection of sequence variants and novel fusion transcripts. Genome Biol 10(10):R115